• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Seattle Genetics

Seattle Genetics

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Global Antibody Drug Conjugates (ADC) Market 2017-2022: Analysis By Drugs, Pipeline Drugs, Regulations: Opportunities and Forecasts - Kadcyla Currently Dominates the ADC Market - Research and Markets

    Global Antibody Drug Conjugates (ADC) Market 2017-2022: Analysis By Drugs, Pipeline Drugs, Regulations: Opportunities and Forecasts - Kadcyla Currently Dominates the ADC Market - Research and Markets

  2. BCMA Targeted Therapies, 2017-2030 - Research and Markets

    BCMA Targeted Therapies, 2017-2030 - Research and Markets

  3. Primecap Odyssey Growth: Stellar Record, Low Fees

    This Gold-rated fund is a fine vehicle for new investors to gain access to the Primecap managers.

  4. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  5. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

  6. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

  7. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

©2017 Morningstar Advisor. All right reserved.